Phase 2 N=50 Ranolazine Among Unrevascularized Chronic Stable Angina Patients
Angina
Primary: Seattle Angina Questionnaire Score Change From Baseline to 16 Weeks — 48; 50; 40; 60 units on a scale — p=>0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=79 Phase II Study of STA-2 in Patients With Chronic Stable Angina
Chronic Stable Angina
Primary: Change in Total Exercise Time — 450.39; 411.15 seconds — p=0.025
Phase 2 N=186 Phase IIb Study of STA-2 in Patients With Chronic Stable Angina
Chronic Stable Angina
Primary: Change in Total Exercise Time (Seconds) — 24.3; 18.2; 33.9; 11.9 second
Phase 4 N=171 An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)
Chronic Angina
Primary: Evaluate the Validity of the WISQ in Women With Chronic Angina Based on Changes in Patient-reported Angina Frequency and Nitroglycerin (NTG) Consumption Before and…
Phase 4 N=949 Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
Angina Pectoris · Coronary Artery Disease · Type 2 Diabetes Mellitus
Primary: Average Weekly Angina Frequency Over the Last 6 Weeks of Treatment — 5.2; 4.5 angina attacks per week — p=0.008
Phase 3 N=2,651 Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
Coronary Artery Disease · Angina Pectoris
Primary: Kaplan-Meier Estimates for Time From Randomization to First Occurrence of Ischemia-driven Revascularization or Ischemia-driven Hospitalization Without Revascularization…
Phase 4 N=402 Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina
Stable Angina · Coronary Disease
Primary: Number of Myocardial Ischemia Attacks in 24 Hours — 2.3; 3.8 ischemic attacks per 24 hours — p=<0.0001
N/A N=142 Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia
Microvascular Coronary Dysfunction (MCD)
Primary: Seattle Angina Questionnaire (SAQ) — 68.09; 66.7; 58.4; 51.17 Units on scale
Phase 4 N=54 Effects of Nicorandil on Angina Symptoms in Patients With Coronary Slow Flow
Slow Coronary Flow · Normal, or Near Normal Coronary Angiography · Stable Angina
Primary: Angina Episode Frequnecy — 2.28; 1.68 episodes per week
Phase 4 N=31 Ranolazine and Microvascular Angina by PET in the Emergency Department
Microvascular Angina
Primary: Coronary Flow Reserve — 1.6; 1.6; 1.9; 1.6 ratio
Phase 4 N=28 Ranolazine in Ischemic Cardiomyopathy
Cardiomyopathy · Chest Pain · Dyspnea
Primary: Anginal Frequency — 86.67; 74.44 units on a scale — p=0.058
Phase 2 N=26 Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)
Microvascular Angina
Primary: Change in Seattle Angina Questionnaire Score Regarding Angina Frequency — 0.70; 0.27 score on a scale
Phase 1 N=64 A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)
Angina Pectoris · Coronary Heart Disease · Calcitonin Gene-related Peptide Receptor
Primary: Number of Participants With Clinical Adverse Events (AEs) — 7; 1; 5 Participants
Phase 4 N=12 Study to Evaluate Effect of Nebivolol on Angina in Women With Microvascular Disease
Microvascular Angina
Primary: Seattle Angina Questionnaire Score — 83.3; 29.2; 74.1; 67.6 units on a scale
Phase 3 N=112 Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina
Chronic Myocardial Ischemia · Refractory Angina Pectoris · Advanced Coronary Heart Disease
Primary: Change From Baseline in Total Exercise Time on Exercise Tolerance Test (ETT) Using the Modified Bruce Protocol — 108.7; 90.0 seconds
Phase 4 N=37 Effects of Ranolazine and Exercise on Daily Physical Activity Trial
Chronic Stable Angina
Primary: Change in Peak Oxygen Consumption (VO2 Max) — 0.03; 0.38; 0.9; 2.1 ml/kg/min — p=>0.05
N/A N=983 Safety Assessment of Angioplasty Procedures
Angiospastic; Disorder
Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants
N/A N=21 PET MYOCARDIAL Blood Flow Comparison to Coronary CTA and CT-FFR
Coronary Artery Disease
Primary: Number of Flow-limiting Coronary Artery Stenosis on CT — 8 Coronary arteries
Phase 4 N=64 Effect of Molsidomine on the Endothelial (Internal Layer of Blood Vessels) Dysfunction in Patients With Angina Pectoris
Stable Angina Pectoris · Atherosclerosis
Primary: Change Versus Baseline in the Score of the EndoPAT in the Two Groups After One Year of Treatment (Month 12). — 330.60; 164.08 Relative change versus baseline (%)
Phase 2 N=95 PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina
Heart Failure · Myocardial Ischemia · Angina Pectoris
Primary: Participants Stopping Exercise Treadmill Test 3 (ETT-3) for Angina at Stage Earlier Than Baseline Exercise Treadmill Test (ETT-B) — 0; 0; 1 Participants
Phase 3 N=47 Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD
Diabetes, Type I · Diabetes, Type II · Angina
Primary: Change in Post-exercise Coronary Vasodilator Reserve — -4; 2 % change
Phase 4 N=81 Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging
Myocardial Perfusion Imaging · Myocardial Ischemia
Primary: Exercise-induced Perfusion Defect Size (PDS) Following Ranolazine and Placebo Treatment — 21.54; 20.87 percentage of myocardium — p=0.29
N/A N=34 Comparative Effectiveness of Decision Aids for Stable Chest Discomfort
Coronary Artery Disease · Stable Angina
Primary: Total Knowledge Score — 2.83; 4.0 knowledge score
Phase 4 N=30 The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina
Coronary Artery Disease
Primary: Change in Coronary Artery Flow From Rest to Isometric Handgrip (IHG) Exercise at the End of the Administration of Febuxostat and Placebo — 8.8; 10.7 mL/min — p=0.756
N/A N=51 PCI Alternative Using Sustained Exercise
Cardiovascular Disease
Primary: Myocardial Perfusion Reserve — 2.76; 2.47; 2.82; 2.52 Ratio
Phase 4 N=33 Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome
Stable Angina · Metabolic Syndrome
Primary: Impact of Ranolazine on Hemoglobin A1C — -5; 2.6 percent change
Phase 2 N=20 Microvascular Coronary Disease In Women: Impact Of Ranolazine
Myocardial Ischemia
Primary: Cardiac Magnetic Resonance (CMRs) — 11.7; 16.0 Percentage of ischemic myocardium
Phase 3 N=11 Ranolazine and Pulmonary Hypertension
Angina · Pulmonary Arterial Hypertension
Primary: Improve Angina Symptoms — 1.75 units on a scale — p=0.0013
N/A N=90 Management of Anger in Patients With Acute Myocardial Infarction (MAPAMI)
Myocardial Infarction
Primary: Difference in Flow-mediated Dilation in the Brachial Artery in the Base and After the Treatment. — 11.24; 7.70 percent change dilatation — p=0.05
N/A N=5,179 International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)
Cardiovascular Diseases · Coronary Disease · Coronary Artery Disease
Primary: Primary Composite Outcome: Death From Cardiovascular Causes, Myocardial Infarction, or Hospitalization for Unstable Angina, Heart Failure, or Resuscitated Cardiac Arrest…